| Business Summary | | Molecular
Devices
Corporation
is
a
developer
of
high-performance
bioanalytical
measurement
systems
that
accelerate
and
improve
drug
discovery
and
other
life
sciences
research.
The
Company's
systems
enable
pharmaceutical
and
biotechnology
companies
to
leverage
advances
in
genomics
and
combinatorial
chemistry
by
facilitating
the
high
throughput
and
cost
effective
identification
and
evaluation
of
drug
candidates.
The
Company's
instrument
systems
are
based
on
its
advanced
core
technologies,
which
integrate
its
expertise
in
engineering,
molecular
and
cell
biology
and
chemistry.
The
Company's
systems
are
fundamental
tools
for
drug
discovery
and
life
sciences
research,
and
its
MAXline
series
of
microplate
readers
and
its
FLIPR
Cell
Analysis
systems
are
market
share
leaders
in
their
respective
markets. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Molecular
Devices
Corporation
designs,
develops,
manufactures
and
markets
proprietary,
high
performance
bioanalytical
measurement
systems
designed
to
improve
the
drug
development
process.
For
the
six
months
ended
6/30/01,
revenues
rose
1%
to
$44.7
million.
Net
income
rose
27%
to
$4.1
million.
Revenues
reflect
increased
sales
of
the
Company's
Flexstation(TM)and
Skatron
product
lines.
Earnings
also
reflect
a
decrease
in
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Joseph Keegan, Ph.D., 47 Pres
and CEO | $535K | $2.5M | Timothy Harkness, 34 VP,
Fin. and CFO | 291K | 1.5M | Robert Murray, 53 VP-Operations | 260K | 823K | Tony Lima, 42 VP
- Sales and Service | 286K | 154K | John Senaldi, 36 VP
of Worldwide Marketing | 254K | 1.8M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|